Topic: New Insights and Emerging Targets in Cancer Drug Resistance

Resistance to chemotherapeutic drugs remains a major problem in cancer treatment. Cancer cells increasingly generate resistance to various chemotherapeutic drugs through intrinsic and acquired mechanisms, leading to cancer relapse. Over the past decades, research advancements have shed light on the genes and molecular signaling mechanisms involved in drug resistance. These emerging mechanisms of resistance have undergone extensive study, with the aim of understanding how to overcome drug resistance in future treatment approaches. A deeper understanding of the mechanisms underlying drug resistance is crucial in guiding future cancer treatments and achieving improved outcomes. Based on the knowledge gained to date, new molecularly targeted drugs and precise drug candidates are being developed and tested in preclinical and clinical studies, in an attempt to overcome drug resistance and enhance drug efficacy. The identification of novel targets and understanding of their role in drug resistance will present opportunities for innovative therapies in combating cancer drug resistance.

For this Special Issue in CDR, we welcome submissions that investigate the intrinsic and acquired resistance mechanisms developed by the use of new therapeutics, and emerging drug targets generating resistance during chemotherapy. Keywords or topics for the Special Issue in CDR.

1. Emerging targets in cancer drug resistance;

2. Drug resistance to novel chemotherapeutic drugs;

3. New insights into and mechanisms of multidrug resistance in cancer (any cancer type);

4. Challenges and opportunities in cancer drug resistance;

5. Mitochondrial alterations during cancer drug resistance;

6. Role of non-coding RNAs (miRNAs and/or long non-coding RNAs) in cancer drug resistance;

7. Drug repurposing to overcome cancer drug resistance;

8. Molecularly targeted agents for overcoming drug resistance;

9. Recent models as carriers to overcome cancer drug resistance. 

31 Jan 2024